EGFR and cancer: Monoclonal antibodies targeting CLDNs, particularly CLDN1 and CLDN4, hold promise as therapeutic agents in the treatment of various cancers, with potential synergistic effects when combined with known anti-cancer agents like 5-fluorouracil and anti-EGFR antibodies.